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BACKGROUND: Despite earlier studies demonstrating in vitro propagation of solid tumour cancer stem cells (CSCs) as non-adherent
tumour spheres, it remains controversial as to whether CSCs can be maintained in vitro. Additional validation of the CSC properties
of tumour spheres would support their use as CSC models and provide an opportunity to discover additional CSC cell surface
markers to aid in CSC detection and potential elimination.
METHODS: Primary tumour cells isolated from 13 surgically resected colon tumour specimens were propagated using serum-free CSC-
selective conditions. The CSC properties of long-term cultured tumour spheres were established and mass spectrometry-based
proteomics performed.
RESULTS: Freshly isolated CD133
þ colorectal cancer cells gave rise to long-term tumour sphere (or spheroids) cultures maintaining
CD133 expression. These spheroid cells were able to self-renew and differentiate into adherent epithelial lineages and recapitulate
the phenotype of the original tumour. Relative to their differentiated progeny, tumour spheroid cells were more resistant to the
chemotherapeutic irinotecan. Finally, CD44, CD166, CD29, CEACAM5, cadherin 17, and biglycan were identified by mass
spectrometry to be enriched in CD133
þ tumour spheroid cells.
CONCLUSION: Our data suggest that ex vivo-expanded colon CSCs isolated from clinical specimens can be maintained in culture
enabling the identification of CSC cell surface-associated proteins.
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Increasing evidence suggests that tumour initiation and metastases
are dependent on a small sub-population of tumour cells termed
cancer stem cells (CSCs) bearing indefinite self-renewal potential
and the capacity to differentiate into diverse populations compris-
ing a tumour. Existence of CSCs was first documented in acute
myelogenous leukaemia, in which only the CD34
þ/CD38
  sub-
population of leukaemic cells was shown to proliferate extensively,
self-renew, and form new tumours (Bonnet and Dick, 1997).
Subsequent studies in solid tumours revealed that CD44
þ/CD24
 
and CD133
þ sub-populations contained CSC populations in breast
cancer and glioblastoma, respectively (Al-Hajj et al, 2003; Singh
et al, 2004) whereas more recent evidence of their existence has
been demonstrated in melanoma (Fang et al, 2005; Schatton et al,
2008), prostate (Patrawala et al, 2006), pancreatic (Li et al, 2007),
and colon cancer (O’Brien et al, 2007; Ricci-Vitiani et al, 2007). In
addition to tumour initiation, another important attribute of CSCs
is their apparent insensitivity to conventional therapies (Bao et al,
2006; Liu et al, 2006; Phillips et al, 2006), hypothesised to
contribute to tumour recurrence. Therapeutic targeting of CSC
sub-populations therefore represents a novel opportunity to
eradicate tumour-initiating, potentially drug-resistant cancer cell
sub-populations (Fan et al, 2006; Piccirillo et al, 2006).
Standard procedures for isolating CSCs from tumour tissues
involve cell sorting of a sub-population on the basis of cell surface
markers and confirmation of their tumour-initiating activity in
xenograft transplantation assays (Clarke et al, 2006). In addition,
in vitro propagation of CSCs applying stem cell culture conditions
has been repeatedly reported. Emerging studies have shown that
CSC populations isolated and expanded from a variety of tumours,
including glioblastomas (Hemmati et al, 2003), melanoma (Fang
et al, 2005), breast (Ponti et al, 2005), lung (Eramo et al, 2008),
ovarian (Bapat et al, 2005; Zhang et al, 2008), and colon cancers
(Ricci-Vitiani et al, 2007; Vermeulen et al, 2008), frequently grow
as non-adherent, three-dimensional (3D) tumour spheres under
serum-free conditions. Despite this evidence, it remains contra-
dictory whether in vitro-cultured CSCs retain their original
phenotype.
Successful cultivation of CSCs in vitro not only enables us to
study CSCs in a more flexible manner but also provides an
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sadditional model in which to test the anti-CSC activity of
individual drug candidates or compound libraries through high-
throughput screening (Gupta et al, 2009). The elucidation of drug
resistance in the CSC population has been made on CD133
þ brain
and colon CSCs, largely because of the ability to propagate these
cells in vitro under a defined serum-free culture condition (Bao
et al, 2006; Liu et al, 2006; Phillips et al, 2006). Expansion of CSCs
in vitro also provides an opportunity to identify cell surface
markers to facilitate their detection, enrichment, and potential
therapeutic targeting through monoclonal antibody-based strate-
gies. To this end, in this study, we generated and expanded tumour
spheres highly enriched in CD133
þ cells from multiple indepen-
dent colon cancer specimens under serum-free culture conditions.
Upon prolonged expansion, CD133
þ tumour spheroid cells
displayed CSC properties, initiated xenograft tumours, and
exhibited resistance to chemotherapy-induced apoptosis. To
identify cell surface proteins enriched on cultured tumour spheres,
mass spectrometry-based quantitative proteomics was performed
on tumour spheres and on the original primary tumour cells from
which they were derived. To our knowledge, this is the first
demonstration of applying mass spectrometry-based quantitative
proteomics to characterise in vitro-expanded CSC populations. In
addition to confirming the expression of cell surface proteins on
CSCs previously identified empirically by flow cytometry, addi-
tional cell surface markers not previously associated with color-
ectal CSCs were also identified.
MATERIALS AND METHODS
Tissue process, cell lines, and cell culture
Tissue specimens obtained from Bio-options, Inc (Fullerton, CA,
USA) and from the North Shore-Long Island Jewish Health System
(Manhasset, NY, USA) were processed within 16h of surgical
removal under appropriate institutional review board approval.
Samples were trimmed, sliced, and enzymatically dissociated in a
phosphate-buffered saline-based buffer containing dispase
(1.5mgml
 1) and DNase (1mgml
 1) for 1h with agitation at
371C. A fraction of single primary cells were cultured in non-
treated polystyrene cell culture flasks at 371C, 5% CO2 in a
humidified atmosphere in a serum-free medium (namely, CSC
medium). To generate CSC medium, mouse embryonic fibroblast-
conditioned human embryonic stem cell (hESC) medium was
mixed with fresh hESC medium at a 1:1 ratio and supplemented
with 4ngml
 1 bFGF, 10ngml
 1 EGF, 10mgml
 1 bovine insulin
(Sigma-Aldrich, St Louis, MO, USA), 5.5mgml
 1 human transfer-
rin (Sigma-Aldrich), and 5ngml
 1 sodium selenite (Sigma-
Aldrich; Fang et al, 2005). Another fraction of cells was cultured
in a serum-containing medium consisting of Dulbecco’s modified
Eagle’s medium supplemented with 20% foetal bovine serum,
0.2mM non-essential amino acids, 1mM sodium pyruvate, and
0.075% sodium bicarbonate.
Cell proliferation and apoptosis assay
Both spheroid and differentiated cells were harvested, disaggre-
gated, plated at 10000 cells per well in 96-well plates, and cultured
in either CSC or serum-containing media, respectively, for 24h to
allow the differentiated population to re-adhere, whereas X90% of
the spheroid-derived cell populations remained as single cells in
suspension with no evidence of differentiation detected. Cells were
then treated with irinotecan (Edwards Medical, Bolingbrook, IL,
USA) or vehicle controls. Cell proliferation and apoptosis assays
were performed on day 4 using Alamar blue reagent (Invitrogen,
Carlsbad, CA, USA) and Apo-One homogeneous caspase-3/7 assay
(Promega, Madison, WI, USA), respectively, following the
manufacturer’s instructions.
Differentiation and limiting dilution assay
Differentiation was induced by culturing in Dulbecco’s modified
Eagle’s medium supplemented with 20% foetal bovine serum,
0.2mM non-essential amino acids, 1mM sodium pyruvate, and
0.075% sodium bicarbonate in flasks coated with 0.3mgml
 1
collagen I (BD Biosciences, San Jose, CA, USA). A limiting dilution
assay was performed to evaluate self-renewal capacity. Briefly,
spheroid cells were dissociated into single cells and plated in 96-
well plates. Final cell dilutions ranged from 5 to 100 cells per well
in 0.2ml of CSC medium. The number of spheres containing more
than four cells was counted after 7 days.
Immunocytochemical staining
Staining was performed as described (Fang et al, 2005). Primary
antibodies specific for CD133 (Miltenyi Biotech, Auburn, CA,
USA), nestin (NES; R&D Systems), musashi-1 (MSI-1; R&D
Systems, Minneapolis, MN, USA), and BMI-1 (Upstate, Billerica,
MA, USA) were used, with primary antibody binding detected
using corresponding Alexa Fluor 488-conjugated secondary
antibodies (Invitrogen). The cells were counterstained with 40,6-
diamidino-2-phenylindole.
Flow cytometry and fluorescence-activated cell sorting
Standard cell surface flow cytometry was used to characterise the
samples with phycoerythrin-conjugated CD133 (Miltenyi Biotech),
APC-conjugated epithelium-specific antigen EpCAM (CD326,
epithelial cell surface antigen, BD Biosciences), and purified
E-cadherin (ZyMed, San Francisco, CA, USA) antibodies. Prolif-
eration and cytokeratin expression were measured simultaneously
using a fluorescein isothiocyanate 5-bromodeoxyuridine (BrdU)
flow kit (BD Biosciences) and anti-cytokeratin antibodies (phy-
coerythrin-conjugated cytokeratin 7/8 (CAM 5.2), BD Biosciences;
or purified cytokeratin 20, Abcam (Cambridge, MA, USA); both
worked similarly in our study). Cell sorting was performed on a
MoFlo High Speed Cell Sorter (Dako, Carpinteria, CA, USA) using
CD133 and EpCAM antibodies.
RNA isolation and real-time reverse transcriptase PCR
Total RNA was isolated from cultured cells using an RNEasy kit
(Qiagen, Valencia, CA, USA), including on-column DNase treat-
ment. Quantitative reverse transcriptase PCR was performed using
TaqMan gene expression assays (Applied Biosystems, Framingham,
MA, USA) on a Prism 7900HT sequence detection system (Applied
Biosystems). Each sample was assayed in triplicate and included a
control well without reverse transcriptase. The following genes
were tested: connexin 43 (CX43) (NM_000165.2; Hs00748445_s1),
BMI-1 (NM_005180.5; Hs00180411_m1), MSI-1 (NM_002442;
Hs00159291_m1), SNAIL1 (NM_005985.2; Hs00195591_m1)
ABCC1 (NM_004996; Hs00219905_m1), ABCA3 (NM_001089.2;
Hs00184543_m1), and ABCG2 (NP_004818; Hs00184979_m1).
Gene expression was quantified relative to 18S rRNA expression,
and copy number was estimated assuming 5 10
6 copies of 18S
rRNA per cell.
Anchorage-independent growth assay
Standard soft-agar assays were performed using a cell transforma-
tion detection assay kit (Chemicon, Billerica, MA, USA). A 0.8%
base agar layer in the serum-containing medium as described
above was prepared in six-well culture plates. Viable cells (2500
cells per well) suspended in 0.3% agar diluted in the same medium
were layered over the base layer. On the top, spheroid and
differentiated cells were provided with CSC and serum-containing
media, respectively, and the media were changed twice a week. To
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sevaluate chemosensitivity, irinotecan (5mM) was included in the
feed medium. After 4 weeks, the number of microscopically visible
colonies (approximately 4100mm in diameter) was counted.
Statistical analysis
Cell proliferation and apoptosis data were statistically analysed
using two-way analysis of variance to assess the difference in
means between spheroid and differentiated cells. If the overall
P-value was significant (Po0.05) between two populations,
Tukey’s post hoc test was used to assess the difference in means
for the two group pairs in a given concentration to preserve a low
false-positive rate. P-value was computed on the basis of
studentised range distribution. All analyses were performed using
SPlus Windows release 7.0.3 (Statistical Sciences, Seattle, WA,
USA). The results shown elsewhere were subjected to a paired
t-test to determine statistical significance. *Po0.05; **Po0.01.
Evaluation of tumourigenicity
Tumourigenicity was determined by subcutaneous injection of
spheroids into the right flank of five SCID-beige mice (Bioqual,
Gaithersburg, MD, USA). Before injection, the spheres were mixed
with Matrigel (BD Biosciences) at a 1:1 ratio. H&E staining
was carried out on paraffin-embedded sections following
standard protocols. Tumour volume (V) was calculated using the
following equation: V¼(a
2 b)/2, where a is the width of the
tumour (small diameter) and b is the length (large diameter), both
in millimetres.
Cell surface protein enrichment and glycopeptide
generation
Epithelial cells were enriched up to B90% from primary cell
populations dissociated from colon tissues through MACS cell
separation columns (Miltenyi Biotech) using an anti-EpCAM
antibody (BD Biosciences). Cultured tumour spheroid cells were
used directly. Dead cells were removed using a dead cell removal
kit (Miltenyi Biotech). Viable cells (X5 10
6 cells in total) were
incubated with 1mM sodium periodate for 10min to oxidise
carbohydrates of glycoproteins in plasma membrane (Bobbitt,
1956; Schiess et al, 2009). After washing with phosphate-buffered
saline, cells were lysed and protein concentration was determined
by DC assay (Bio-Rad Laboratories, Hercules, CA, USA). Oxidised
glycoproteins in the lysate were conjugated to hydrazide resin
(Bio-Rad Laboratories) at 41C overnight with gentle shaking. After
removal of non-glycoproteins by thorough washing steps (2 M
NaCl, 2% SDS, 200mM propanol amine (0.1 M NaOAc, pH 5.5),
40% Ethanol, and 80% ethanol), bound proteins were reduced with
dithiothreitol and alkylated with ICAT (light reagent, Applied
Biosystems). Alkylated proteins were digested with trypsin (371C
overnight). Glycopeptide-bound resins were washed sequentially
with 2 M NaCl, 80% ACN/0.1% TFA, 100% MeOH, and 0.1 M
NH4HCO3, followed by PNGase F (New England Biolabs, Ipswich,
MA, USA) digestion at 371C overnight to release the glycopeptides.
LC–MS and LC–MS/MS analysis
Glycopeptides were loaded on a trap column (C18, Grace Vydac
238EV5, 50mm 150mm, 5mm) and washed for 10min using 3%
buffer B (0.1% formic acid in 90% acetonitrile). Peptides were
separated over a C18 monomeric column (Grace Vydac 238EV5,
150mm 150mm, 5mm) at a flow rate of 1.5mlmin
 1 using an
Agilent 1100 HPLC system (Santa Clara, CA, USA). Peptides were
eluted from the column using a gradient, 3–30% buffer B in
215min, 30–90% buffer B in 30min. The eluted peptides were
analysed using an online QSTAR Pulsar (MDS/Sciex, Toronto, ON,
Canada) equipped with an electrospray ionisation source. For
liquid chromatography–mass spectrometry (LC–MS) analysis, a
3-s accumulation time was used and data were collected over the
mass range of 400–1500m/z. For liquid chromatography–mass
spectrometry/mass spectrometry (LC–MS/MS) analysis, a 1-s
TOF–MS, followed by two 10-s MS/MS scans, was acquired and
data were collected over the mass range of 400–1500m/z for the
TOF-MS scan and 60–2000m/z in MS/MS mode. Searches were
performed using MASCOT (Matrix Science, Boston, MA, USA)
with the Mass Spectrometry protein sequence DataBase (MSDB
Imperial College London, London, UK). LC–MS wiff files were
transformed to the list of ions using peak detection software
ReSpect (PPL, Isleham, UK).
Proteomic data analysis
For multi-sample analysis, peptide ion peaks of LC–MS maps from
individual samples were aligned on the basis of mass to charge
ratio (m/z), corrected retention time (Rt), and charge state (z)a s
described previously (Kim et al, 2009). After intensity normal-
isation, the list of aligned peptide ions was loaded into Spotfire
(Spotfire Inc, Somerville, MA, USA) for differential analysis.
Peptides with overexpressed intensity ratios were subjected to LC–
MS/MS-based peptide sequencing.
RESULTS
Isolation and expansion of CD133
þ colon cancer-derived
tumour spheres displaying capacity for self-renewal and
differentiation
Thirteen independent surgically resected colon tumour specimens
of varying pathology stages, together with matched adjacent
normal tissue, were dissected to obtain single cell suspensions.
Twelve specimens (92%) were derived from primary adenocarci-
nomas or mucinous adenocarcinomas and one (8%) from a
metastatic adenocarcinoma (Table 1). As CD133 has been reported
to be a CSC marker for colon cancers, we determined CD133
epithelial cell surface expression levels by flow cytometry. Of 13
tumour samples, 9 comprised of CD133
þ sub-populations
representing 420% of epithelial cells co-staining for EpCAM,
with one late-stage tumour (case 12) exhibiting CD133 expression
on 85% of the EpCAM
þ population (Table 1). In contrast, CD133
expression was substantially lower (o5.5%) in the normal
adjacent epithelial cells. We next evaluated the growth potential
of these primary cells under serum-free conditions as detailed in
the Materials and Methods section. As shown in Table 1, sphere-
forming characteristics were frequently observed in colon tumour
cells (10 of 13) and less in matched adjacent normal tissue cell
populations (2 of 13). Sphere formation was observed from both
unsorted colon cancer specimens and from those cases (3, 4, 10,
and 11) subjected to enrichment by flow cytometry for the CD133-
expressing population (Table 1). Approximately 1 in 1 10
5–
2.5 10
6 primary tumour cells was capable of forming highly
compact spheres (or spheroids). These non-adherent, multi-
cellular spheroids usually appeared within 7 days and the majority
(B77%) survived in culture for B8 weeks (Figure 1A). During
culture, colon tumour spheres frequently became adherent and
adopted an epithelial morphology (Figure 1A). To confirm the
sphere-forming potential resides within CD133-expressing cells,
CD133
þ/EpCAM
þ cells and CD133
 /EpCAM
þ sub-populations
were purified from four independent colon tumour specimens
(cases 3, 4, 10, and 12). By fluorescence-activated cell sorting,
fractionated populations demonstrating purity of 92–95%
(CD133
þ/EpCAM
þ) and 94–98% (CD133
 /EpCAM
þ) were
obtained. Within 8 weeks, although all four CD133-enriched
populations gave rise to spheroids in the serum-free growth
medium, none of the four CD133
  populations were capable of
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capability does reside within the CD133-expressing population.
To further characterise colon cancer-derived tumour spheres,
effort was made to expand them in vitro through prolonged serum-
free culture. Three tumour sphere cultures including two (cases 5
and 13) established from unsorted primary tumour cells and
another expanded from the CD133
þ/EpCAM
þ fraction isolated
from case 11 were all sustained in culture for more than 5 months.
To evaluate more longitudinal changes in the tumour sphere
cultures, those derived from case 11 were maintained in culture for
more than 22 months, with analysis of BrdU incorporation at
months 3, 10, and 15 revealing no change in proliferation rate.
Conversely, in a serum-containing Dulbecco’s modified Eagle’s
medium, primary cell populations derived from the same speci-
men generated adherent cultures with a heterogeneous morpho
logy (Figure 1B; upper left panel). Immunofluoroscence staining
shows that tumour spheroid cells, but not adherent cells, expressed
colon CSC marker CD133 (Figure 1B; lower panels). These
adherent cells underwent senescence within approximately 4–6
weeks. Data presented below are the representative results from
the three prolonged spheroid cultures, except for where specified.
Under serum-free, stem cell selective culture conditions, B90%
of these tumour spheroid cells were positive for CD133/EpCAM, as
demonstrated by flow cytometry (Figure 1C). The observation that
a fraction of dissociated spheroid cells persistently generated new
tumour spheres demonstrates their capacity for self-renewal
(Figure 1D).
To investigate whether tumour spheroid cells retain tumouri-
genic potential upon prolonged passaging, 100 spheres (containing
B5 10
4 viable cells or 4.5 10
4 CD133
þ cells) from tumour
spheres cultured for over 6 months were injected subcutaneously
into the flank of SCID-Beige mice. After 14 weeks, four of five
injected mice developed tumours with a mean tumour volume of
336mm
3 (±34; s.d.). The H&E-stained section of tumours derived
from colon tumour spheroid cells showed fibrous tissues contain-
ing adenocarcinoma with foci of necrosis and calcification,
histologically identical to the original human colon cancer
(Figure 1E and Table 1).
Differentiation capacity of CD133
þ tumour spheroid cells
derived from clinical specimens
Consistent with observations made with other colon tumour
spheres in early cultures, during prolonged propagation, B5% of
colon tumour spheroid cells spontaneously became adherent and
gained epitheloid morphology, indicating differentiation capacity.
Meanwhile, single cell-derived clonal populations were obtained
from long-term colon tumour spheroid cultures for further
characterisation of their differentiation potentials. When removed
of growth factors and exposed to 20% serum-containing medium,
a significant fraction of clonal cultures (B70–90%) became
adherent. As tumour spheres differentiated, cells migrated out of
the adherent spherical colony to form a flat monolayer with typical
epitheloid morphology (Figure 2A). After differentiation, the
fraction of cells expressing colon epithelium-specific cytokeratin
20 increased significantly (B90% compared with 26%), whereas
BrdU incorporation was observed in B40% of differentiated cells
compared with B10% of undifferentiated tumour spheroid cells
(Figure 2B). Increases in the number of cells expressing E-cadherin
and elevated CX43 mRNA levels in the resulting adherent cells
confirm differentiation towards epithelial cellular organisation
(Figure 2C). A concomitant decrease in the expression of Snail,a
known transcriptional repressor of E-cadherin and a key regulator
of epithelial–mesenchymal transition, was also observed during
differentiation (Figure 2C).
Colon cancer-derived CD133
þ tumour spheroid cells
express a panel of stem cell markers and drug transporter
ABCG2 gene
The colon cancer derived tumour spheres obtained in this study
were evaluated for expression of a panel of stem cell markers,
Table 1 Summary of patient population, tumour sample information and sphere-forming capability
Case Age/sex Tumour stage Tissue type Expression of CD133
+/EpCAM
+ population (%) Sphere formation
1 84/F Stage I Normal adjacent tissue 2.78 No
(T2, N0, MX, G3) Adenocarcinoma 0.26 No
2 92/F Stage I Normal adjacent tissue 3.46 No
(T2, N0, MX, G2) Adenocarcinoma 4.30 No
3 61/F Stage I Normal adjacent tissue 1.00 No
(T2, N0, MX, G2) Adenocarcinoma 53.46 Yes
a
4 88/F Stage I Normal adjacent tissue 3.90 No
(T2, N0, M0, G2) Adenocarcinoma 23.00 Yes
a
5 36/F Stage I Normal adjacent tissue 0.40 No
(T2, N0, MX, G2) Mucinous adenocarcinoma 3.72 Yes
6 76/F Stage IIA Normal adjacent tissue 0.62 No
(T3, N0, MX, G2) Adenocarcinoma 36.51 No
7 85/F Stage IIA Normal adjacent tissue 3.50 N/A
(T3, N0, M0, G2) Mucinous adenocarcinoma 29.50 Yes
8 51/F Stage IIA Normal adjacent tissue 0.90 No
(T3, N0, MX, G3) Adenocarcinoma 4.36 Yes
9 59/M Stage IIA Normal adjacent tissue 0.34 No
(T3, N0, MX, G2) Adenocarcinoma 45.48 Yes
10 84/F Stage IIIB Normal adjacent tissue 5.22 No
(T3, N1, MX, G2) Mucinous adenocarcinoma 36.52 Yes
a
11 62/M Stage IIIC Normal adjacent tissue 1.09 Yes
(T4, N2, MX, G2) Adenocarcinoma 36.41 Yes
a
12 70/F Stage IIIC Normal adjacent tissue 1.53 Yes
(T3, N2, MX, G2) Adenocarcinoma 84.65 Yes
13 38/F Stage IV Normal adjacent tissue 4.19 No
(T4, N2, M1, G2) Adenocarcinoma (metastasis) 39.49 Yes
Abbreviations: F¼female; M¼male; N/A¼not available (due to contamination).
aCell sorting performed. Sphere formation was observed only in the CD133
+/EpCAM
+
fraction, but not in the CD133
 /EpCAM
+ fraction.
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sincluding BMI-1, nestin (NES), and musashi-1 (MSI-1). As shown
in Figure 3A, immunofluorescent staining identified B30–40% of
tumour spheroid cells expressing NES, BMI-1, and MSI-1.
Differentiation to an adherent epitheloid phenotype is accompa-
nied by a clear decrease in the percentage of cells expressing NES,
BMI-1, and MSI-1 (Figure 3B). Consistent with their stem cell
properties, real-time reverse transcriptase PCR analyses demon-
strate expression of ABCC1 and ABCG2 genes in CD133
þ colon
cancer tumour spheroid cells (Figure 3C). In contrast, no
detectable expression of a third member, the ABCA3 gene, was
observed. On differentiation, the level of ABCG2 mRNA but not of
ABCC1 mRNA is reduced over 10-fold (Figure 3C).
Colon tumour spheroid cells are more resistant to
standard chemotherapy than differentiated progeny
To determine whether colon tumour spheres display drug
resistance, their sensitivity to irinotecan, a component of first-
and second-line treatment agents for advanced colon cancer, was
first examined in an anchorage-independent growth assay.
Compared with counterpart differentiated cell populations,
tumour spheroid cells derived from primary tissue display
significantly increased resistance to irinotecan-mediated inhibition
of anchorage-independent growth as measured both by colony
number and size (Figure 4A). Similarly, in cell culture, evaluation
of tumour spheres that disaggregated into single cell suspensions
demonstrated that they are more resistant, compared with their
differentiated progeny, to irinotecan across a wide range of
irinotecan concentrations (Figure 4B). Whereas 450% of differ-
entiated cells were growth inhibited by 2mM irinotecan, 40% of
spheroid cells were resistant to growth inhibition at 135mM, the
highest concentration of irinotecan tested (Figure 4B). Resistance
to irinotecan-mediated inhibition of cell growth is at least partly
contributed by the inability of colon tumour spheres to undergo
apoptosis as measured by caspase-3/7 levels (Figure 4C).
Application of mass spectrometry-based proteomics to
identify cell surface-associated proteins expressed on colon
tumour spheres
To identify candidate cell surface proteins associated with colon
CSCs, a mass spectrometry-based proteomics approach was used.
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Figure 1 Sphere-forming primary colon tumour cells under stem cell culture conditions retain CD133 expression and tumourigenic potential. (A)
Formation of non-adherent, three-dimensional (3D) spheroids was observed within 4 weeks in the cultures of primary tumour cells derived from the
majority of tumour samples tested (left; bar, 150mm). In extended culture over a month, some tumour spheroids may become adherent (arrows) and
partially differentiated into adherent cell populations (middle; bar, 300mm). A closeup of the boxed area in the middle panel shows the morphology of
epithelial lineages differentiated from a tumour sphere (right; bar, 75mm). (B) Morphology of adherent cells and non-adherent tumour spheres derived from
a sorted CD133
þ/EpCAM
þ population in serum-containing and serum-free media, respectively (top panel). Cell surface staining of CD133 expression
(green) was detected by immunofluorescent staining in spheroid populations, whereas their serum-driven adherent counterparts lost the expressiono f
CD133 (bottom panel). Nuclei were counterstained with 40,6-diamidino-2-phenylindole (DAPI) (blue). Bar, 50mm. (C) Flow cytometry analysis shows that
89.20% of spheroid cells are positive for CD133/EpCAM. (D) A fraction of clonally derived spheroid cells reform spheroids in self-renewal assays
(mean±s.d., n¼5). (E) Histology of representative xenografted tumours derived from whole-tumour spheres (haematoxylin and eosin (H&E) staining;
 10 objective).
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enriched in tumourigenic CD133
þ colon tumour spheroid cells
using the original tumour cell population from which tumour
spheroid cells were derived as the baseline. A 490% enriched
epithelial cell population obtained from the resected colon tumour
tissue from patient 11 was processed to facilitate the capture of
glycosylated cell surface peptides (details in the Materials and
Methods section). Peptides from cell surface were captured in a
similar manner from the CD133
þ tumour spheroid cells expanded
from the same patient specimen. LC–MS intensity profiles of the
tryptic glycopeptides obtained from each population reveal that
B5% of the peptides identified show a greater than four-fold
difference in their level of expression (Figure 5A). These peptide
ions were then subjected to MS/MS sequencing. As anticipated,
among the proteins identified to be enriched was CD133. Two
glycopeptides from CD133 were identified to be overexpressed in
the tumour spheroid population, relative to the primary colon
cancer sample (Table 2). Other proteins identified by at least two
glycopeptides as overexpressed on tumour spheres include proteins
previously associated with colon CSCs: CD44 and CD166. Elevated
intensities of CD133 and CD44 proteins in tumour spheroid cells are
shown as examples (Figure 5B). Additional cell surface-associated
proteins identified as elevated in colon CSCs included CEACAM5,
cadherin 17, CD29, and biglycan.
DISCUSSION
Considering the role of CSCs in driving new tumour formation,
spread and recurrence and facilitation of drug resistance, it is of
interest to understand their biological properties and design
therapeutic strategies to aid their elimination (Dick, 2009). CSCs
have been isolated primarily by enrichment using empirically
derived cell surface markers, followed by confirmation of their
tumourigenesis in immunodeficient mice, such as NOD/SCID
mice. For example, in breast cancer, the CD44
þ/CD24
 /low sub-
population, which comprises B11–35% of the total cell popula-
tion, has been shown to be the population of cells capable of
driving tumour formation with as few as 200 cells (Al-Hajj et al,
2003). Subsequently, CSC populations in brain (Singh et al, 2004),
colon (O’Brien et al, 2007; Ricci-Vitiani et al, 2007), and lung
(Eramo et al, 2008) cancers have also been demonstrated to reside
in the CD133
þ sub-population, using the xenotransplantation
approach. Despite the success of the approach based on cell sorting
and in vivo propagation of the tumour-initiating population to
characterise CSC populations in various tumour types, such an in
vivo system provides limited material for in-depth molecular and
cellular characterisation.
Several key biological properties, including self-renewal and
differentiation, are shared by both normal stem cells and CSCs,
leading to the term ‘cancer stem cells’ for the tumour-initiating
sub-population in human malignancies. Interestingly, although
originally designated for in vitro propagation of human embryonic
and adult stem cells, serum-free culture conditions supplemented
with growth factors have been successfully applied to cultivate
CSCs derived from solid tumours. Such a growth characteristic was
first demonstrated in brain tumours, in which application of a
culture condition used to support cultivation of neural stem cells
led to the successful isolation of 3D neurospheres bearing CSC
properties from human brain tumours (Hemmati et al, 2003; Singh
et al, 2003). Similar tumour spheres enriched for CSC populations
have been documented in breast (Ponti et al, 2005), melanoma
(Fang et al, 2005), lung (Eramo et al, 2008), ovary (Zhang et al,
2008), and colon (Ricci-Vitiani et al, 2007; Todaro et al, 2007;
Vermeulen et al, 2008) cancers. Strikingly, in comparison with
serum-driven counterparts, cells derived under serum-free culture
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Figure 4 Resistance of colon tumour spheroid cells to standard care chemotherapeutic agent. (A) In anchorage-independent assays, after treatment with
irinotecan, the number and total sizes of colonies formed by tumour spheroid populations are greater/larger than those formed by adherent populations
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tumour spheroid cells are less sensitive to irinotecan-induced growth inhibition and drug-induced apoptosis in comparison with their differentiated adherent
counterparts. Apoptosis results are shown as the ratio of the result of treatment with irinotecan over the result of untreated cells as a control, or the ratio of
increased caspase-3/7 activity of treatment with irinotecan over the result of untreated cells as a baseline. *Po0.05; **Po0.01.
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sconditions seem to share more similarities with original tumours,
suggesting that they provide a more biologically relevant culture
system than that provided by widely used traditional cancer cell
lines (Lee et al, 2006; De Witt Hamer et al, 2008).
In this study, we applied a serum-free culture condition
previously proven in both normal and malignant stem cell systems
(Fang et al, 2005; Yu et al, 2006) to cultivate colon CSCs from
primary tissues. Tumour sphere formation was observed within 8
weeks for 10 of 13 freshly obtained colorectal tumour specimens
processed to obtain viable epithelial cell suspensions. The three
specimens from which no tumour spheres were obtained were
stage I or stage IIA, raising the possibility that the inability to
derive tumour spheres was due to their smaller size and
presumably relatively lower CSC content. Interestingly, sphere
formation was observed in two normal tissue samples obtained
from stage IIIC patients (cases 11 and 12). However, the resulting
spheroid cells survived in culture for a relatively shorter period of
time compared with their tumour counterparts. Whether these
spheres originated from normal colon epithelial stem cells or from
invasive and migrating CSCs demands further analyses of the
normal adjacent tissue-derived spheroid cells. As controls,
adherent primary cultures were also generated under traditional
culture conditions using a serum-containing medium. However,
the resulting adherent cells lost CD133 expression and exhibited a
relatively shorter lifespan compared with spheroid cultures. None
proliferated longer than 2 months in our study, indicating that
these cells may represent tumour stromal cells or differentiated
cancer cells. Our results are in agreement with the earlier study
reporting that a serum-containing condition failed to propagate
CD133
þ cells in vitro (Ricci-Vitiani et al, 2007). In contrast,
multiple tumour sphere cultures could be sustained in culture for
more than 5 months, including one continually cultured for over
22 months that demonstrated the ability to recapitulate the original
tumour phenotype from which it was derived, indicating retention
of CSC properties. More detailed in vivo studies including limiting
dilution studies will be required to determine the percentage of
cells within the expanded tumour sphere populations that exhibits
CSC properties as performed previously for freshly isolated
CD133
þ-enriched populations (O’Brien et al, 2007) or CD133
þ
short-term passaged tumour spheres (Ricci-Vitiani et al, 2007;
Vermeulen et al, 2008).
Considering recent reports associating CD133 expression with
colon CSCs, flow cytometry analysis was performed to determine
the level of CD133 expression on the resected starting specimens.
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0.26–84.65% of the total cell population, with an average of 30.59%
(s.d.: 24.03%), compared with 0.4–5.22% with an average of 2.23%
(s.d.: 1.67%) in case-matched normal adjacent tissues. The results
of our analyses of CD133 expression in colon cancer are somewhat
higher than that reported previously (1.8–25%; O’Brien et al, 2007;
Ricci-Vitiani et al, 2007) and more in accordance with those more
recently reported by Shmelkov et al (2008) in primary human
colon tumours. In our approach, we analyse tumour cells
immediately after resection by flow cytometry and have also
observed high levels of CD133 expression on colon cancer tumour
specimens subjected to mass spectrometry-based proteomics (Van
Orden et al, 2007). Considering the high level of CD133 expression
observed on colon cancer tumour cells in some patient samples
and the belief that CSCs are only a small sub-population of tumour
specimens, our results suggest that CD133 may not be a marker
exclusively expressed on functional CSCs. However, the observa-
tion that only sorted CD133
þ tumour cells and not CD133
  cells
supported tumour sphere formation as shown for cases 3, 4, 10,
and 11 indicates that the CSC population does reside within the
CD133
þ cell population (Table 1). Taken together, these observa-
tions underscore the need for additional markers to further define
the CSC population in colorectal cancer.
The availability of colon tumour spheroid cells derived under
serum-free conditions enabled us to further characterise their
capability for differentiation. Removal of growth factors and
addition of serum facilitate differentiation of colon CD133
þ CSCs
in vitro (Ricci-Vitiani et al, 2007; Vermeulen et al, 2008). In
agreement with this finding, we reproducibly observed a
differentiation of colon tumour spheres on exposure to serum-
containing conditions. The cells became adherent to the substrate
of culture flasks rapidly and adapted epithelial morphology. After
differentiation, CD133-expressing cells declined from 89.20% in
the spheroid populations to 40.5% in the differentiated adherent
population (data not shown). The change in CD133 expression was
accompanied with increases in proliferation rate and in the
fraction of cells expressing E-cadherin and cytokeratin 20.
Consistent with the increase in E-cadherin expression, differentia-
tion led to a decrease in Snail, a transcription factor known to
repress E-cadherin expression and direct epithelial–mesenchymal
transition (Cano et al, 2000). The elevated expression of Snail and
the decreased expression of E-cadherin in the expanded colon
tumour spheres are in line with recent studies indicating that CSCs
may be a product of epithelial–mesenchymal transition (Mani
et al, 2008).
We also assessed additional stem cell and CSC markers,
including transcription factor BMI-1, which contributes to
proliferative capacity and self-renewal of both normal and
malignant stem cells (Lessard and Sauvageau, 2003), and nestin
(NES) and musashi-1 (MSI-1), both of which are markers for
various stem cell populations, including human colon epithelial
stem cells (Nishimura et al, 2003). Examination of the expression
of stem cell markers NES, BMI-1, and MSI-1 revealed expression in
30–40% of tumour sphere-containing cells compared with o5% of
differentiated cells, supporting a view that tumour spheres are not
a homogenous cell population but rather a cancer population
enriched in CD133 cells retaining CSC properties. Despite the lack
of direct evidence for colon cancer, the correlation of elevated
CD133 cancer populations in tumour spheres with enriched
epithelial–mesenchymal transition and stem cell marker proper-
ties is consistent with observations in high-grade brain tumours
that elevated CD133 expression correlates with poor prognosis
(Beier et al, 2008; Rebetz et al, 2008).
Drug resistance has been long recognised as one of the major
obstacles to effective chemotherapy and radiotherapy of cancer
patients. One potential mechanism responsible for drug resistance
of cancer cells is the existence of a sub-population of cells within
heterogeneous tumours that are inherently resistant to the
treatments. Resistance of CSC populations to therapy was first
reported in human acute myeloid leukaemia CD34
þ/CD38
  stem
cells (Costello et al, 2000). Since then, resistance to chemotherapy
and/or radiotherapy has been linked to CSC sub-populations in
various solid tumours, including glioblastoma (Bao et al, 2006; Liu
et al, 2006; Salmaggi et al, 2006), breast (Phillips et al, 2006), lung
(Eramo et al, 2008) and colon (Todaro et al, 2007) cancers.
Consistent with previous studies, our results confirm that colon
CSCs exhibit enhanced resistance to the standard chemotherapeu-
tic agent irinotecan compared with their serum-cultured differ-
entiated derivatives. In our drug sensitivity experiments,
measurement of cell proliferation has been normalised by
vehicle-treated corresponding controls that serve as internal
controls. Therefore, the differential response to drug treatment
between monolayer (differentiated) and 3D (CSC) cultures seems
to result from their intrinsic property, rather than from their
physiological differences under distinct culture conditions (2D vs
3D). Similar to many other agents in the same class, irinotecan
specifically targets rapidly dividing and proliferating cells. Escape
of CSC sub-populations from irinotecan-mediated cell toxicity may
be attributed to their relatively quiescent proliferating state of
cultured CSCs. Furthermore, ATP binding cassette (ABC) drug
transporters such as ABCG2 are known to mediate resistance to
chemotherapeutics and high levels of ABC drug transporters are
suggested to attribute to drug resistance in CSCs (Zhou et al,
2008). In our study, we unveil an elevated expression of ABCG2 in
colon cancer tumour spheres, which is also anticipated to have a
critical role in drug resistance of colon CSCs.
It is of importance that, in addition to facilitating analyses of
drug-resistance mechanisms and its applicability in compound
screening, the ability to expand CSC-enriched populations in vitro
provides a sufficient number of cells for analyses by emerging
technologies such as mass spectrometry-based proteomics. The
proteomic approach directly evaluates global changes in protein
expression and identifies cell surface proteins that are over-
expressed relative to the original tumour population. Identification
of proteins preferably expressed in CSC populations offers novel
opportunities to better define and isolate CSCs and potentially
provides the basis for the development of targeted therapies
to eliminate tumour-initiating cell populations. To this end,
we performed proteomic analyses of colon spheroid cells in
Table 2 Overexpressed proteins detected by proteomic analyses
Protein
Average ratio of
overexpression
a
(s.d.) Peptide detected
CD166 5.7 (1.6) TVNSLNVSAISIPEHDEADEISDENR
IIISPEENVTLTCTAENQLER
LGDCISEDSYPDGNITWYR
Biglycan 22.1 (2.6) MIENGSLSFLPTLR
LLQVVYLHSNNITK
CD44 39.6 AFNSTLPTMAQMEK
Cadherin 17 3.8 (1.2) APKPVEMVENSTDPHPIK
KQDTPQYNLTIEVSDKDFK
GPHFTFSLGSGSLQNDWEVSKINGTHAR
CEACAM5 3.8 (1.3) LQLSNGNRTLTLFNVTR
NSGLYTCQANNSASGHSR
RSDSVILNVLYGPDAPTISPLNTSYR
SDSVILNVLYGPDAPTISPLNTSYR
TLTLFNVTRNDTASYK
ITPNNNGTYACFVSNLATGR
CD29 28.4 SAVGTLSANSSNVIQLIIDAYNSLSSEVILENGK
CD133 4.8 (3.8) LPIQDILSAFSVYVNNTESYIHR
ILASLDFAQNFITNNTSSVIIEETKK
aOverexpression ratio was calculated using normalised intensities of each peptide
detected in spheroid vs primary cell (before cultivation) samples.
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same patient specimen before expansion as colon cancer tumour
spheres. To reduce the complexity of the analyses and to identify
changes in proteins that could be potentially amenable to
monoclonal antibody-based cell sorting or therapeutic-based
strategies, we restricted our focus to the cell surface proteome.
Comparison between expanded tumour spheres and the original
tumour from which it was identified revealed significant changes
in the cell surface peptide expression profile. On the basis of the
flow cytometry analysis of the common cancer tumour spheres,
MS/MS sequence analyses identified a seven-fold increase in the
level of CD133 expression in colon tumour spheres. In addition,
overexpression of at least two peptides corresponding to CD166,
CD44, CD29, CEACAM5, biglycan, and cadherin 17 was detected in
the colon tumour spheres. CD44 has previously been claimed to be
a more robust marker for colon CSC isolation by fluorescence-
activated cell sorting (Dalerba et al, 2007), and our studies here
indicated an approximately 40-fold increase in CD44 expression in
the tumour sphere culture compared with the expression observed
in the epithelial component of the original tumour. CD166 and
CD29 expressions have also been reported to be associated
with the colon CSC population (Dalerba et al, 2007; Vermeulen
et al, 2008), supporting the CSC-enriched properties of the colon
tumour spheres expanded here. In addition, novel cell surface
markers associated with CD133
þ colon CSCs are identified,
including CEACAM5, biglycan, and cadherin 17. The roles of
these cell membrane proteins in cancer development are well
documented. For instance, expression of CEACAMs is associated
with poor prognosis in colon cancer (Ishida et al, 2004) and they
are considered as a therapeutic target (Blumenthal et al, 2005).
Overexpression of biglycan has been identified in pancreatic
cancers (Weber et al, 2001). Cadherin 17, also called liver intestine
cadherin, is implicated for its role in intestinal cell fate
determination, as well as in colon neoplastic development (Hinoi
et al, 2002). Relatively higher expression levels of these proteins in
CD133
þ colon CSC populations implicate their potential as
additional colon CSC markers and as therapeutic targets.
Combined, our data demonstrate that colon CSCs can be
isolated and propagated under serum-free, stem cell culture
conditions. These tumour spheroid cells retain the expression of
well-known cell surface markers, including CD133, CD166, CD44,
and EpCAM, as well as other stem cell-associated proteins such
as NES, BMI-1, and MSI-1. Colon tumour spheroid cells also
exhibit drug resistance to conventional therapy, and possess the
capacity for differentiation and tumourigenesis. It is important
that colon spheroid CSCs are able to generate tumours that
recapitulate the phenotypic heterogeneity and characteristics
found in original tumours. Therefore, these cultures resemble
colon CSCs identified in freshly isolated tumour specimens and
thus provide an in vitro tumour model for comprehensive
biological analysis of CSC populations, as well as for compound
screening. In addition, we identified novel cell surface proteins
associated with CD133
þ colon CSCs, including CEACAM5,
biglycan, and cadherin 17.
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